



PRESS RELEASE

MolMed S.p.A. – integration of the press release dated July 31th 2020 relating to the co-optation of four new Directors

Milan (Italy), August 6th 2020 – as integration of the press release issued on July 31st, 2020 relating to the co-optation of four new Directors, MolMed S.p.A. (MLMD.MI) (“**MolMed**” or the “**Company**”), with reference to the compensation in favour of the Managing Director for the case of termination of office due to the good leaver hypothesis, specifies that such termination of office will happen at the date of the Shareholders' Meeting for the appointment of the entire Administrative Body (day on which the resignation of the Director Laura Iris Ferro will be effective and, therefore, the entire Board of Directors will lapse). The said Shareholders' Meeting shall meet only following AGC's experiment of the procedures referred to by Articles 108, paragraph 2, and 111 of Legislative Decree no. 58/1998 and, therefore, after MolMed delisting by the MTA. The procedure for transactions between related parties will therefore not apply.

For more details regarding the aforementioned procedures and the relative timing, please refer to the AGC press release dated July 29th, 2020 (<https://www.molmed.com/sites/default/files/2020-07/Press%20release%20-%20Sell-out%20procedure.pdf>)

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed's is also developing its CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit www.molmed.com.



PRESS RELEASE

For further information:

MolMed S.p.A.

Investor Relations & Communication Department

MolMed S.p.A.

+39 02 21277.205

investor.relations@molmed.com

Tommasina Cazzato

Press Office

Community Group

+39 345 7357751

tommasina.cazzato@communitygroup.it